Skip to main navigation

About Us

Our Company

Overview Management Team Board of Directors Scientific Advisory Board Partners & Collaborations

Contact

Our Pipeline

Pipeline

Overview Azenosertib

Clinical Trials

Our Approach

Integrated Discovery Engine

Our advanced approach to efficiently identifying and developing novel oncology therapies.

Supporting Publications

Investors & Media

Investor Home

News & Events

Press Releases Events & Presentations

Stock Information

Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage

Financials & Filings

SEC Filings

Corporate Governance

Documents & Charters Management Team Board of Directors Scientific Advisory Committee Committee Composition

Investor Resources

Investor FAQs Investor Contact Email Alerts

Careers

Working at Zentalis

Be part of a vibrant team committed to our common goal: to better the lives of patients impacted by cancer.

Job Opportunities

Investors & Media

Press Releases

Investor Relations Menu

Investor Home

News & Events

Press Releases Events & Presentations

Stock Information

Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage

Financials & Filings

SEC Filings

Corporate Governance

Documents & Charters Management Team Board of Directors Scientific Advisory Board Committee Composition

Investor Resources

Investor FAQs Investor Contact Email Alerts

Contact

Elizabeth Pingpank Hickin
Vice President, Investor Relations
ehickin@zentalis.com

Year

Jun 18, 2024

Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

Jun 03, 2024

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2024

Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 29, 2024

Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors

May 23, 2024

Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting

May 14, 2024

Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit

May 07, 2024

Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress

May 01, 2024

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 02, 2024

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

Apr 01, 2024

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 28

Science Center

10275 Science Center Drive
Suite 200
San Diego, CA 92121

About Us

Our Company Management Team Board of Directors Scientific Advisory Board Partners & Collaborations Contact

Our Pipeline

Overview Azenosertib Clinical Trials

Our Approach

Integrated Discovery Engine Supporting Publications

Investors & Media

News & Events Stock Information Financials & Filings Corporate Governance Investor Resources

Privacy Policy

Terms of Use

Expanded Access Policy

Site Map

Careers